Global Red Blood Cell Products Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Red Blood Cell Products market size was valued at US$ 21090 million in 2024 and is forecast to a readjusted size of USD 25270 million by 2031 with a CAGR of 2.6% during review period.
Red blood cell products are component blood made by separating red blood cells from whole blood through techniques such as centrifugation, filtration, washing, and freezing, and adding anticoagulants or preservation solutions. Its main component is hemoglobin rich red blood cells, which have complete oxygen carrying function and usually remove most of the plasma, white blood cells or platelets. It is mainly used for patients with normal blood volume but need to improve blood oxygen carrying capacity, such as acute bleeding, chronic anemia, surgical blood preparation, etc. Common types include red blood cell suspension, concentrated red blood cells, washed red blood cells, frozen red blood cells, irradiated red blood cells, etc.
Red blood cell products, as an important component of the blood products industry, have shown a stable growth trend in their market size. The aging population is a long-term factor driving market growth. The treatment of age-related diseases such as orthopedic and cardiovascular diseases often requires support from red blood cell products. The changes in disease spectrum also affect the market pattern of red blood cell products. Chronic diseases such as renal insufficiency, malignant tumors, and inflammatory bowel disease are often accompanied by chronic anemia, requiring regular infusion of red blood cells to maintain quality of life. The development of trauma and emergency medicine has enabled more severe trauma patients to receive treatment, and the management of major bleeding cannot be separated from the support of red blood cell products. In addition, advances in medical technology, increased medical expenses, and improved medical security have also promoted the development of the market. The global competitive landscape is highly concentrated and stable, with multinational giants such as CSL, Grifols, Takeda, Octapharma, etc., occupying an absolute advantage in the international market with their global layout, complete product lines, and advanced technology. They not only have a huge plasma collection network, but also continue to invest in research and development innovation, leading the technological development direction of red blood cell products. The competition for plasma station resources is the core focus of competition in the red blood cell products industry. Enterprises are strengthening their layout in areas with abundant plasma station resources, increasing the number of plasma stations through new construction or acquisition, in order to consolidate their advantage in raw material supply. In the future, the market size will continue to grow, but the growth rate may tend to flatten out. Upgrading product structure, technological innovation, improving plasma comprehensive utilization level, expanding clinical applications, increasing industry concentration, international competition and cooperation, and evolving policy environment will become the main development trends in the market. In the future, enterprises with the ability to guarantee raw materials, technological innovation, and market sensitivity will gain competitive advantages and lead the industry towards high-quality development. Despite facing multiple challenges such as raw material limitations, policy constraints, and alternative technologies, the long-term prospects of this market remain broad based on the irreplaceable position of red blood cells in clinical treatment and the continuously growing medical demand.
This report is a detailed and comprehensive analysis for global Red Blood Cell Products market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Red Blood Cell Products market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Red Blood Cell Products
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Red Blood Cell Products market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Kamada, Takeda Pharmaceutical, Kedrion, Grifols, Hemophilia Federation Europe, CSL Behring, Octapharma, LFB Group, American Red Cross, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Red Blood Cell Products market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Red Blood Cell Suspension
Concentrated Red Blood Cells
Washed Red Blood Cells
Irradiated Red Blood Cells
Frozen Red Blood Cells
Others
Market segment by Application
Anemia Treatment
Acute Hemorrhage
Blood Disease Supportive Treatment
Special Disease Management
Major players covered
Emergent BioSolutions
Kamada
Takeda Pharmaceutical
Kedrion
Grifols
Hemophilia Federation Europe
CSL Behring
Octapharma
LFB Group
American Red Cross
Biotest
Sangamo Therapeutics
China National Biotec Group
Hualan Biological
Shanghai RAAS Blood Products
Tiantan Biological
Bohui Innovation
Pilin Biological
Weiguang Biological
Boyaa Bio-pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Red Blood Cell Products product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Red Blood Cell Products, with price, sales quantity, revenue, and global market share of Red Blood Cell Products from 2020 to 2025.
Chapter 3, the Red Blood Cell Products competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Red Blood Cell Products breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Red Blood Cell Products market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Red Blood Cell Products.
Chapter 14 and 15, to describe Red Blood Cell Products sales channel, distributors, customers, research findings and conclusion.
Red blood cell products are component blood made by separating red blood cells from whole blood through techniques such as centrifugation, filtration, washing, and freezing, and adding anticoagulants or preservation solutions. Its main component is hemoglobin rich red blood cells, which have complete oxygen carrying function and usually remove most of the plasma, white blood cells or platelets. It is mainly used for patients with normal blood volume but need to improve blood oxygen carrying capacity, such as acute bleeding, chronic anemia, surgical blood preparation, etc. Common types include red blood cell suspension, concentrated red blood cells, washed red blood cells, frozen red blood cells, irradiated red blood cells, etc.
Red blood cell products, as an important component of the blood products industry, have shown a stable growth trend in their market size. The aging population is a long-term factor driving market growth. The treatment of age-related diseases such as orthopedic and cardiovascular diseases often requires support from red blood cell products. The changes in disease spectrum also affect the market pattern of red blood cell products. Chronic diseases such as renal insufficiency, malignant tumors, and inflammatory bowel disease are often accompanied by chronic anemia, requiring regular infusion of red blood cells to maintain quality of life. The development of trauma and emergency medicine has enabled more severe trauma patients to receive treatment, and the management of major bleeding cannot be separated from the support of red blood cell products. In addition, advances in medical technology, increased medical expenses, and improved medical security have also promoted the development of the market. The global competitive landscape is highly concentrated and stable, with multinational giants such as CSL, Grifols, Takeda, Octapharma, etc., occupying an absolute advantage in the international market with their global layout, complete product lines, and advanced technology. They not only have a huge plasma collection network, but also continue to invest in research and development innovation, leading the technological development direction of red blood cell products. The competition for plasma station resources is the core focus of competition in the red blood cell products industry. Enterprises are strengthening their layout in areas with abundant plasma station resources, increasing the number of plasma stations through new construction or acquisition, in order to consolidate their advantage in raw material supply. In the future, the market size will continue to grow, but the growth rate may tend to flatten out. Upgrading product structure, technological innovation, improving plasma comprehensive utilization level, expanding clinical applications, increasing industry concentration, international competition and cooperation, and evolving policy environment will become the main development trends in the market. In the future, enterprises with the ability to guarantee raw materials, technological innovation, and market sensitivity will gain competitive advantages and lead the industry towards high-quality development. Despite facing multiple challenges such as raw material limitations, policy constraints, and alternative technologies, the long-term prospects of this market remain broad based on the irreplaceable position of red blood cells in clinical treatment and the continuously growing medical demand.
This report is a detailed and comprehensive analysis for global Red Blood Cell Products market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Red Blood Cell Products market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Red Blood Cell Products market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Red Blood Cell Products
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Red Blood Cell Products market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Kamada, Takeda Pharmaceutical, Kedrion, Grifols, Hemophilia Federation Europe, CSL Behring, Octapharma, LFB Group, American Red Cross, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Red Blood Cell Products market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Red Blood Cell Suspension
Concentrated Red Blood Cells
Washed Red Blood Cells
Irradiated Red Blood Cells
Frozen Red Blood Cells
Others
Market segment by Application
Anemia Treatment
Acute Hemorrhage
Blood Disease Supportive Treatment
Special Disease Management
Major players covered
Emergent BioSolutions
Kamada
Takeda Pharmaceutical
Kedrion
Grifols
Hemophilia Federation Europe
CSL Behring
Octapharma
LFB Group
American Red Cross
Biotest
Sangamo Therapeutics
China National Biotec Group
Hualan Biological
Shanghai RAAS Blood Products
Tiantan Biological
Bohui Innovation
Pilin Biological
Weiguang Biological
Boyaa Bio-pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Red Blood Cell Products product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Red Blood Cell Products, with price, sales quantity, revenue, and global market share of Red Blood Cell Products from 2020 to 2025.
Chapter 3, the Red Blood Cell Products competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Red Blood Cell Products breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Red Blood Cell Products market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Red Blood Cell Products.
Chapter 14 and 15, to describe Red Blood Cell Products sales channel, distributors, customers, research findings and conclusion.
Table of Contents
133 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Red Blood Cell Products by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
